rttnews.comSEP 152 min read$TEVA

Teva Transitions To Direct Listing On NYSE

Teva Pharmaceutical (TEVA) will transition to direct listing on NYSE, continuing to trade on NYSE and TASE. The move is part of its Pivot to Growth strategy. The company reported 40% revenue growth in 2025, with 2026 revenues estimated at $3.7B. TEVA closed Friday at $37.09, up 2.04%, and Monday at $38.72, up 4.39%.

Original reporting

rttnews.com

Published Sep 15, 2026, 5:30 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 15, 2026, 6:15 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · rttnews.com

Decision brief

The 30-second read

$TEVABullishMed

Why it matters

The direct listing aims to broaden investor access and support growth strategy.

Market read

Corporate action that may affect TEVA's liquidity and investor base.

What to watch

Potential tax and regulatory implications for existing ADR holders.

Relevance 7/10Novelty 7/10Timing: Monday announcement

Background

Teva is a global generic medicines supplier listed on NYSE via ADS.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEVABullishMedium confidence

Context

Teva announced transition to a direct listing on the NYSE, ending its ADS program.

Expected impact

Potential modest upside as new investors gain access.

Evidence & confidence

Listing change is a corporate action that typically lifts trading interest, but no immediate financial impact is disclosed.

Market effects

Sector

May set a precedent for other ADR issuers considering direct listings.

Regional

Limited to US and Israeli markets where TEVA trades.

Global

Minor, primarily affects TEVA shareholders.

Counterpoint

What could challenge this read

The listing change could introduce volatility without clear upside.

Key entities

Company
Teva Pharmaceutical Industries Ltd.
Issuer of the direct listing announcement.

Read at source ← All news

SEP 12

$TEVAHighAI 8/10

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Teva (TEVA) agreed to a $125M bid for BioXcel Therapeutics' (BTAI) assets, including Igalmi and BXCL501, with $57.5M upfront and $67.5M in milestones. BioXcel filed for bankruptcy, shares dropped 70%. Teva aims to expand its neuroscience portfolio, following a $700M acquisition in June.

yahoo.com3 min

SEP 12

$TEVAMedAI 8/10

Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment

Teva Pharmaceuticals (TEVA) announced the FDA accepted its NDA for TEV-'749, a new schizophrenia treatment. The once-monthly injection showed efficacy and safety in late-stage trials. TEV-'749 aims to improve patient adherence by eliminating post-injection monitoring. Shares traded marginally lower. TEVA stock has more than doubled over the past year.

stocktwits.com2 min

SEP 11

$TEVAMedAI 9/10

Teva raises USD 4.9bn to refinance higher-coupon debt

Teva Pharmaceutical (TEVA) raised USD 4.9bn via senior notes to refinance higher-coupon debt. The offering includes EUR 1.5bn and USD 3.2bn across five tranches maturing 2032-2037. Proceeds will redeem notes due 2028-2031, reducing interest expense and refinancing risk. The company aims to lower debt burden from its 2016 acquisition of Actavis Generics.

allsci.com2 min

SEP 10

$TEVAMedAI 9/10

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Teva Pharmaceutical Industries Ltd. (TEVA) announced the successful pricing of approximately $4.9 billion in senior notes. The proceeds will fund redemptions of certain existing notes, pay related fees, and be used for general corporate purposes, including debt repayment. The notes are expected to settle on or about September 16, 2026, subject to customary closing conditions.

montrealgazette.com2 min

SEP 9

$TEVAMed

After credit upgrade, Teva plans to recycle debt

Teva Pharmaceutical (NYSE: TEVA) received investment-grade debt ratings from all three major agencies. It plans to issue new bonds to repay existing higher-interest debt, totaling $1.25B, $398M, and up to $450M in USD, plus up to €1.25B in euros. The move aims to reduce interest costs and improve financial flexibility, following a strategy to return to growth. Teva's debt stood at $16.6B at Q2's end, with 27% short-term. The company will also switch to trading ordinary shares on NYSE instead of

globes.co.il2 min

SEP 7

$ALCLow

Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs

President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).

tradingview.com3 min